JP2013516450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516450A5 JP2013516450A5 JP2012547546A JP2012547546A JP2013516450A5 JP 2013516450 A5 JP2013516450 A5 JP 2013516450A5 JP 2012547546 A JP2012547546 A JP 2012547546A JP 2012547546 A JP2012547546 A JP 2012547546A JP 2013516450 A5 JP2013516450 A5 JP 2013516450A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- composition according
- composition
- protein
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1000318.4A GB201000318D0 (en) | 2010-01-08 | 2010-01-08 | Method of treatment |
| GB1000318.4 | 2010-01-08 | ||
| GB1005071.4 | 2010-03-25 | ||
| GBGB1005071.4A GB201005071D0 (en) | 2010-03-25 | 2010-03-25 | Method of treatment |
| PCT/GB2011/000022 WO2011083317A1 (en) | 2010-01-08 | 2011-01-10 | Ev576 for use in the treatment of viral infections of the respiratory tract |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516450A JP2013516450A (ja) | 2013-05-13 |
| JP2013516450A5 true JP2013516450A5 (https=) | 2014-02-13 |
| JP5840623B2 JP5840623B2 (ja) | 2016-01-06 |
Family
ID=44305222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547546A Active JP5840623B2 (ja) | 2010-01-08 | 2011-01-10 | 気道のウイルス感染症の治療に用いるｅｖ５７６ |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20120283167A1 (https=) |
| EP (1) | EP2521562B1 (https=) |
| JP (1) | JP5840623B2 (https=) |
| CN (1) | CN102762223B (https=) |
| AU (2) | AU2011204483B2 (https=) |
| CA (1) | CA2785612C (https=) |
| NZ (1) | NZ601018A (https=) |
| PL (1) | PL2521562T3 (https=) |
| WO (1) | WO2011083317A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3119802B1 (en) * | 2014-03-20 | 2019-12-04 | InflaRx GmbH | Inhibitors of c5a for the treatment of viral pneumonia |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| GB201602802D0 (en) | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| ES2945433T3 (es) | 2017-04-21 | 2023-07-03 | Volution Immuno Pharmaceuticals Sa | Coversina para el tratamiento de enfermedades ampollares autoinmunes |
| MA51147A (fr) | 2017-12-13 | 2021-03-24 | Regeneron Pharma | Associations d'anticorps anti-c5 et utilisations associées |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| US20220047673A1 (en) * | 2018-09-10 | 2022-02-17 | Volution Immuno Pharmaceuticals Sa | Coversin for Use in the Treatment of Rheumatic Diseases |
| GB201905810D0 (en) | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US12097222B2 (en) | 2019-06-06 | 2024-09-24 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| WO2020247610A1 (en) | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases |
| JP2023503776A (ja) | 2019-09-27 | 2023-02-01 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20230218571A1 (en) * | 2020-04-01 | 2023-07-13 | Thiogenesis Therapeutics, Inc. | Cysteamine precursor compounds for the treatment of betacoronavirus infections |
| EP4146168A4 (en) * | 2020-05-08 | 2024-06-12 | Kodiak Sciences Inc. | USE OF IL-6 ANTIBODIES AND VEGF TRAPS AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993017099A1 (en) | 1992-02-27 | 1993-09-02 | Merck & Co., Inc. | Protein for inhibiting collagen-stimulated platelet aggregation |
| US7884066B2 (en) | 1999-10-05 | 2011-02-08 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
| US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| JP4772667B2 (ja) * | 2003-06-02 | 2011-09-14 | エヴォルーテック・リミテッド | 補体阻害剤 |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2007117241A1 (en) * | 2006-04-12 | 2007-10-18 | Biocryst Pharmaceuticals, Inc. | Intramuscular antiviral treatments |
| US7274999B1 (en) * | 2006-03-10 | 2007-09-25 | Atmel Corporation | Brownout detector system and method |
| PL2061501T3 (pl) | 2006-09-08 | 2016-01-29 | Volution Immuno Pharmaceuticals Sa | Sposób leczenia zaburzeń oddechowych |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
-
2011
- 2011-01-10 AU AU2011204483A patent/AU2011204483B2/en active Active
- 2011-01-10 JP JP2012547546A patent/JP5840623B2/ja active Active
- 2011-01-10 PL PL11700973T patent/PL2521562T3/pl unknown
- 2011-01-10 NZ NZ601018A patent/NZ601018A/xx not_active IP Right Cessation
- 2011-01-10 US US13/521,011 patent/US20120283167A1/en not_active Abandoned
- 2011-01-10 EP EP11700973.8A patent/EP2521562B1/en active Active
- 2011-01-10 CN CN201180005464.6A patent/CN102762223B/zh active Active
- 2011-01-10 CA CA2785612A patent/CA2785612C/en active Active
- 2011-01-10 WO PCT/GB2011/000022 patent/WO2011083317A1/en not_active Ceased
-
2015
- 2015-01-02 US US14/588,616 patent/US9522171B2/en active Active
-
2016
- 2016-05-11 AU AU2016203058A patent/AU2016203058B2/en active Active
- 2016-07-22 US US15/217,601 patent/US20170065677A1/en not_active Abandoned
-
2019
- 2019-06-07 US US16/434,737 patent/US20200155646A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516450A5 (https=) | ||
| Honce et al. | Obesity-related microenvironment promotes emergence of virulent influenza virus strains | |
| Tuvim et al. | Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia | |
| Ilyushina et al. | Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia | |
| Herold et al. | Influenza virus-induced lung injury: pathogenesis and implications for treatment | |
| Florescu et al. | The complex link between influenza and severe sepsis | |
| Marathe et al. | Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A (H5N1) virus infection in mice | |
| Belser et al. | DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection | |
| Yen et al. | Pandemic influenza as a current threat | |
| Liu et al. | Characteristics of human infection with avian influenza viruses and development of new antiviral agents | |
| CY1122291T1 (el) | Αναστολeις ιικου αναδιπλασιασμου | |
| KR101440629B1 (ko) | 바이러스 감염을 시스테아민 화합물로 치료하는 물질들 및방법들 | |
| Hu et al. | PA-X: a key regulator of influenza A virus pathogenicity and host immune responses | |
| Meseko et al. | Antiviral options and therapeutics against influenza: history, latest developments and future prospects | |
| Choi et al. | Differential microRNA expression following infection with a mouse-adapted, highly virulent avian H5N2 virus | |
| Horman et al. | The drivers of pathology in zoonotic avian influenza: the interplay between host and pathogen | |
| Ludwig | Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. | |
| Yang et al. | Lianhua‐Qingwen Displays Antiviral and Anti‐Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model | |
| Bray | Highly pathogenic RNA viral infections: challenges for antiviral research | |
| Cai et al. | 14-Deoxy-11, 12-didehydroandrographolide attenuates excessive inflammatory responses and protects mice lethally challenged with highly pathogenic A (H5N1) influenza viruses | |
| Noah et al. | Adapting global influenza management strategies to address emerging viruses | |
| Kahn et al. | Swine and influenza: a challenge to one health research | |
| Tan et al. | An overview of the characteristics of the novel avian influenza A H7N9 virus in humans | |
| JP2013503880A5 (https=) | ||
| Guo et al. | Genetic and biological properties of H10N3 avian influenza viruses: A potential pandemic candidate? |